Absence of resistance mutations in antiretroviral-naive patients treated with ritonavir-boosted saquinavir

Antiviral Therapy

Volumn 11, Issue 5, 2006, Pages 631-635

  Ananworanich, Jintanat ^a   Hirschel, Bernard ^b   Sirivichayakul, Sunee ^c   Ubolyam, Sasiwimol ^a   Jupimai, Thidarat ^a   Prasithsirikul, Wisit ^d   Chetchotisakd, Ploenchan ^e   Kiertiburanakul, Sasisopin ^f   Munsakul, Warangkana ^g   Raksakulkarn, Phitsanu ^h   Tansuphasawadikul, Somboon ⁱ   Schutz, Malte ^j   Snowden, Wendy ^k   Ruxrungtham, Kiat ^a,c  

^a THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c CHULALONGKORN UNIVERSITY   (Thailand)

^d Bamrasnaradura Infectious Disease Institute   (Thailand)

^e KHON KAEN UNIVERSITY   (Thailand)

^f MAHIDOL UNIVERSITY   (Thailand)

^g NAVAMINDRADHIRAJ UNIVERSITY   (Thailand)

^h Sanpatong Hospital   (Thailand)

ⁱ Buddhachinnaraj Hospital   (Thailand)

^j HOFFMANN LA ROCHE INC   (United States)

^k ROCHE PRODUCTS LTD   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; LAMIVUDINE; PROTEINASE; RITONAVIR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR DISOPROXIL;

ADULT; ARTICLE; CONTROLLED STUDY; ENZYME ASSAY; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REBOUND; VIRUS INFECTION; VIRUS ISOLATION; VIRUS LOAD; VIRUS MUTATION;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MALE; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; SAQUINAVIR; THAILAND; TREATMENT FAILURE; VIRAL LOAD;

EID: 33747766878     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Schneider MF, Gange SJ, Williams CM, et al. Patterns of the hazard of death after AIDS through the evolution of antiretroviral therapy: 1984-2004. AIDS 2005; 19:2009-2018.
2. McCutchan FE, Hegerich PA, Brennan TP, et al. Genetic variants of HIV-1 in Thailand. AIDS Res Hum Retroviruses 1992; 8:1887-1895.
3. Carr JK, Salminen MO, Koch C, Gotte D, et al. Full-length sequence and mosaic structure of a human immunodeficiency virus type 1 isolate from Thailand. J Virol 1996; 70:5935-5943.
4. Ananworanich J, Ruxrungtham K, Siangphoe U, et al. A prospective cohort study of efficacy and safety of 2 NRTIs plus once-daily ritonavir-boosted saquinavir hard gel capsule (SQV-HGC/r) at 24 weeks. Antivir Ther 2005; 10:761-767.
5. Sirivichayakul S, Ruxrungtham K, Ungsedhapand C, et al. Nucleoside analogue mutations and Q151M in HIV-1 subtype A/E infection treated with nucleoside reverse transcriptase inhibitors. AIDS 2003; 17:1889-1896.
6. Johnson VA, Brun-Vézinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: 2005. Top HIV Med 2005; 13:125-131.
7. Kozal MJ, Shah N, Shen N, et al. Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Nat Med 1996; 2:753-759.
8. Hsu LY, Subramaniam R, Bacheler L, Paton NI. Characterization of mutations in CRF01_AE virus isolates from antiretroviral treatment-naive and -experienced patients in Singapore. J Acquir Immune Defic Syndr 2005; 38:5-13.
9. Deeks SG, Hellmann NS, Grant RM, et al. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome. J Infect Dis 1999; 179:1375-1381.
10. Parkin NT, Deeks SG, Wrin MT, et al. Loss of antiretroviral drug susceptibility at low viral load during early virological failure in treatment-experienced patients. AIDS 2000; 14:2877-2887.
11. Mouroux M, Yvon-Groussin A, Peytavin G, et al. Early virological failure in naive human immunodeficiency virus patients receiving saquinavir (soft gel capsule)-stavudine-zalcitabine (MIKADO trial) is not associated with mutations conferring viral resistance. J Clin Microbiol 2000; 38:2726-2730.
12. Parkin N, Lie Y, Hellmann NS, Petropoulos CJ, Markowitz M, Ho D. Correspondence. J Infect Dis 2000; 181:1863-1864.
13. Parkin N, Chappey C and the ViroLogic Clinical Reference Laboratory. Discordance between genotype-based predictions of protease inhibitor susceptibility and actual phenotype in HIV_1 isolates containing mutations at positions 82 or 90: modulatory effects of mutations at positions 46 and 54. Antivir Ther 2000; 5 Suppl 3:50.
14. Lolekha R, Sirivichayakul S, Siangphoe U, et al. Resistance to dual nucleoside reverse-transcriptase inhibitors in children infected with HIV clade A/E. Clin Infect Dis 2005; 40:309-312.
15. Vella S, Palmisano L. The global status of resistance to antiretroviral drugs. Clin Infect Dis 2005; 41 Suppl 4:S239-S246.
16. Staszewski S, Stark T, Knecht G, et al. The QUAD study: a pilot study to assess the efficacy and safety of Trizivir + RTV-boosted saquinavir (TZV+SQVR) compared to Combivir + RTV-boosted saquinavir (CBV+SQVR) in ART-naive patients with high viral load (VL) and low CD4 count. 24 week interim analysis. 9th European AIDS Conference, Warsaw, Poland. 25-29 October 2003. Abstract F1/1.
17. Kempf DJ, King MS, Bernstein B, et al. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J Infect Dis 2004; 189:51-60.
18. MacManus S, Yates PJ, Elston RC, White S, Richards N, Snowden W. GW433908/ritonavir once daily in antiretroviral therapy-naive HIV-infected patients: absence of protease resistance at 48 weeks. AIDS 2004; 18:651-655.
19. Salama C, Caplivski D. Development of atazanavir resistance mutations in a clinical setting amongst patients without evidence of pre-existing mutations. Antivir Ther 2005; 10:530.
20. Colonno R, Rose R, McLaren C, Thiry A, Parkin N, Friborg J. Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens. J Infect Dis 2004; 189:1802-1810.
21. MacManus S, Yates P, White S, Richards N, Snowden W. GW433908 in ART-naive subjects: absence of resistance at 48 weeks with boosted regimen and APV-like resistance profile with unboosted regimen. 10th Conference on Retroviruses and Opportunistic Infections, Boston, USA. 10-14 February 2003. Abstract 598.
22. Turriziani O, Antonelli G, Jacobsen H, et al. Identification of an amino acid substitution involved in the reduction of sensitivity of HIV-1 to an inhibitor of viral proteinase. Acta Virologica 1994; 38:297-298.
23. Winters MA, Schapiro JM, Lawrence J, Merigan TC. Human immunodeficiency virus type 1 protease genotypes and in vitro protease inhibitor susceptibilities of isolates from individuals who were switched to other protease inhibitors after long-term saquinavir treatment. J Virol 1998; 72:5303-5306.
24. Ananworanich J, Sirivichayakul S, Ubolyam S, et al. Different incidence of protease resistance in patients failing treatment on an initial ritonavir-boosted saquinavir (saquinavir/r) regimen versus those with prior exposure to dual-nucleosides and unboosted saquinavir. Quebec, Canada. 7-10 June 2004. Abstract 33.
25. Chittick GE, Zong I, Blum MR, et al. Pharmacokinetics of tenofovir disoproxil fumarate and ritonavir-boosted saquinavir mesylate administered alone or in combination at steady state. Antimicrob Agents Chemother 2006; 50:1304-1310.
26. Ananworanich J, Siangphoe U, Mahanontharit A, Hill A, Hirschel B, Ruxrungtham K. Saquinavir trough concentration before and after switching NRTI to tenofovir in patients treated with once-daily saquinavir hard gel capsule/ritonavir 1600 mg/100 mg. Antivir Ther 2004; 9:1035-1036.